Page 5 - ப்ளூம்பெர்க் கீம்மேல் நிறுவனம் க்கு புற்றுநோய் நோயெதிர்ப்பு சிகிச்சை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from ப்ளூம்பெர்க் கீம்மேல் நிறுவனம் க்கு புற்றுநோய் நோயெதிர்ப்பு சிகிச்சை. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In ப்ளூம்பெர்க் கீம்மேல் நிறுவனம் க்கு புற்றுநோய் நோயெதிர்ப்பு சிகிச்சை Today - Breaking & Trending Today

Gut microbe may play a role in the development of breast cancers


Gut microbe may play a role in the development of breast cancers
A microbe found in the colon and commonly associated with the development of colitis and colon cancer also may play a role in the development of some breast cancers, according to new research from investigators with the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy. Breast tissue cells exposed to this toxin retain a long-term memory, increasing the risk for disease.
In a series of laboratory experiments, researchers discovered that when enterotoxigenic Bacteroides fragilis (ETBF) was introduced to the guts or breast ducts of mice, it always induced growth and metastatic progression of tumor cells. A description of the work is published in the January 6 issue of the journal ....

Sheetal Parida , Dipali Sharma , Emily Henderson , Bloomberg Kimmel Institute For Cancer Immunotherapy , Johns Hopkins Kimmel Cancer Center , Kimmel Institute , Johns Hopkins , தாள் பாரிட , டிபாலி ஷர்மா , எமிலி ஹென்டர்சன் , ப்ளூம்பெர்க் கீம்மேல் நிறுவனம் க்கு புற்றுநோய் நோயெதிர்ப்பு சிகிச்சை , ஜான்ஸ் ஹாப்கின்ஸ் கீம்மேல் புற்றுநோய் மையம் , கீம்மேல் நிறுவனம் , ஜான்ஸ் ஹாப்கின்ஸ் ,

Drugs create balancing act for patients with non-small cell lung cancer


 E-Mail
The results of a large, retrospective study of patients who received a form of immunotherapy for non-small cell lung cancer (NSCLC) revealed that patients may get more than one immune-related side effect, and identified a correlation between these multisystem immune-related adverse events (irAEs) and improved patient survival. In fact, patients who developed two irAEs did better, in terms of delaying the time to cancer progression and overall survival, than those who developed only one irAE. According to the researchers, this new information will be helpful in discussing with patients the spectrum of immune side effects that may occur from immunotherapy and the implications for their survival. ....

Johns Hopkins Hospital , United States , North Carolina , Ohio State University , National Institutes Of Health , Dana Farber Cancer Institute , East Carolina University , Dwight Owen , Shunichi Sugawara , Christine Hann , Abdul Rafeh Naqash , Gregory Otterson , David Ettinger , Paul Walker , Jiajia Zhang , Bairavi Shankar , Julie Brahmer , Josephine Feliciano , Biagio Ricciuti , Patrick Forde , Sandip Patel , Jarushka Naidoo , Kristen Marrone , James Comprehensive Cancer Center , University Of Perugia , Kimmel Cancer Center ,